DGX Stock Recent News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.

Quest Diagnostics (DGX 5.49%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day.

Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Jim Davis - President & CEO Sam Samad - EVP & CFO Shawn Bevec - VP, IR Conference Call Participants Kevin Caliendo - UBS Patrick Donnelley - Citi Michael Cherny - Leerink Partners Joanna Zhou - Evercore ISI Pito Chickering - Deutsche Bank David Westenberg - Piper Sandler Andrew Brackmann - William Blair Noah Kava - Jefferies Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics Fourth Quarter and Full-Year 2024 Conference Call. At the request of the company, this call is being recorded.

Quest Diagnostics (DGX 6.36%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18.

Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.15 per share a year ago.

Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80 SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024.